For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 25,626 | 19,911* | 20,012 | 21,369 |
| General and administrative | 7,609 | 3,703* | 5,981 | 5,714 |
| Total operating expenses | 33,235 | 23,613 | 25,993 | 27,083 |
| Loss from operations | -33,235 | -23,613* | -25,993 | -27,083 |
| Interest income | 760 | 50* | 419 | 241 |
| Change in fair value of the tranche rights | - | 0* | 0 | 0 |
| Other income (expense), net | -113 | 4,991* | -5 | 22 |
| Total other income | 647 | 5,041* | 414 | 263 |
| Net loss | -32,588 | -18,573 | -25,579 | -26,820 |
| Basic EPS | -1.08 | -0.132 | -0.13 | -0.2 |
| Diluted EPS | -1.08 | -0.132 | -0.13 | -0.2 |
| Basic Average Shares | 30,136,324 | 140,991,124 | 193,897,764 | 132,175,202 |
| Diluted Average Shares | 30,136,324 | 140,991,124 | 193,897,764 | 132,175,202 |
IMMUNIC, INC. (IMUX)
IMMUNIC, INC. (IMUX)